Emerging agents for the therapy of advanced prostate cancer.
about
Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic reviewThe Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance.Current status of clinical trials assessing oncolytic virus therapy for urological cancers.Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches.Contemporary approaches to prostate cancer management.Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.Role of exosomal small RNA in prostate cancer metastasis
P2860
Q26748872-25B34714-8A34-40EF-A8AD-BC77A91BC0F5Q38681199-058E0B32-BB12-487E-B1EE-B0BA5ACA331DQ38741837-878563E9-6743-4529-8C96-8D19F177522BQ38771880-4CFBF135-7A6E-404A-9B18-F879D178AFD1Q38953424-772E5812-829C-4A19-B4DB-D13E1215198AQ39093352-3B044B4B-C32F-404F-9BA0-E97C115B3823Q57489975-074B59FD-C1B3-43C0-AAA7-7591E1B268DB
P2860
Emerging agents for the therapy of advanced prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Emerging agents for the therapy of advanced prostate cancer.
@en
type
label
Emerging agents for the therapy of advanced prostate cancer.
@en
prefLabel
Emerging agents for the therapy of advanced prostate cancer.
@en
P2093
P2860
P356
P1433
P1476
Emerging agents for the therapy of advanced prostate cancer.
@en
P2093
Amanda R Hathaway
Guru Sonpavde
Mary Katherine Baker
P2860
P304
P356
10.2217/FON.15.224
P407
P577
2015-09-14T00:00:00Z